IVA Inventiva S.A. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1756594 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 9.20M | 17.48M |
| R&D expense | 90.88M | 110.01M |
| SG&A expense | 15.84M | 13.84M |
| Operating income | -97.56M | -102.71M |
| Interest expense | 12.18M | 5.18M |
| Income tax | 313,000 | 607,000 |
| Net income | -184.21M | -110.43M |
| EPS (basic) | -3.08 | -2.43 |
| EPS (diluted) | -3.08 | -2.43 |
| Weighted avg. shares (diluted) | 59.78M | 45.35M |
| Balance sheet | ||
| Cash & equivalents | 96.56M | 26.92M |
| Short-term investments | — | 10,000 |
| Receivables | 531,000 | 3.81M |
| Inventory | 0 | 417,000 |
| Current assets | 111.51M | 48.19M |
| PP&E, netmay include right-of-use assets (IFRS) | 5.00M | 9.12M |
| Intangibles | 48,000 | 541,000 |
| Total assets | 118.97M | 69.56M |
| Current liabilities | 120.73M | 50.16M |
| Total liabilities | 225.61M | 101.59M |
| Shareholders' equity | -106.65M | -32.03M |
| Shares outstanding | 95.66M | 52.12M |
| Cash flow statement | ||
| Operating cash flow | -85.93M | -81.61M |
| Investing cash flow | 8.74M | -7.73M |
| Financing cash flow | 145.59M | 29.08M |
| Stock-based compensation | 3.58M | 3.97M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.